One percent tenofovir applied topically to humanized BLT Mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the blt model for evaluation of new microbicide candidates

Journal of Virology

Volumn 85, Issue 15, 2011, Pages 7582-7593

  Denton, Paul W ^a   Othieno, Florence ^b,i   Martinez Torres, Francisco ^a   Zou, Wei ^a   Krisko, John F ^a   Fleming, Elisa ^b   Zein, Sima ^b   Powell, Daniel A ^b,j   Wahl, Angela ^a,k   Kwak, Youn Tae ^b   Welch, Brett D ^c   Kay, Michael S ^c   Payne, Deborah A ^d,l   Gallay, Philippe ^e   Appella, Ettore ^f   Estes, Jacob D ^g   Lu, Min ^h   Garcia, J Victor ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g SAIC FREDERICK INC   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^j UNIVERSITY OF MARYLAND   (United States)

^k BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^l Unipath   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; C PEPTIDE FUSION INHIBITOR C52L; CHEMOKINE RECEPTOR CCR5; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; MEMBRANE DISRUPTING AMPHIPATHIC PEPTIDE INHIBITOR C5A; MICROBICIDE; TC 247; TENOFOVIR; TRIMERIC ZINC FINGER INHIBITOR PIE12 TRIMER; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG PROTEIN BINDING; FEMALE; GENITAL SYSTEM; HEALTH PROGRAM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MEMBRANE RECONSTITUTION; MOTHER CHILD RELATION; MOUSE; NONHUMAN; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; VAGINA DISEASE; VAGINAL HUMAN IMMUNODEFICIENCY VIRUS INFECTION; VAGINITIS; VIRUS ENTRY; VIRUS INHIBITION; VIRUS TRANSMISSION;

ADENINE; ADMINISTRATION, TOPICAL; ANIMALS; BASE SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CHIMERA; DISEASE MODELS, ANIMAL; DNA PRIMERS; DRUG EVALUATION, PRECLINICAL; FEMALE; HIV INFECTIONS; HUMANS; MICE; PHOSPHONIC ACIDS; RECEPTORS, CCR5; REVERSE TRANSCRIPTASE INHIBITORS; VAGINA;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 79960417636     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00537-11     Document Type: Article

References (57)

1. Abdool Karim, Q., et al. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329:1168-1174.
2. Amatya, R., et al. 2004. Lymphocyte immunophenotype reference ranges in healthy Indian adults: implications for management of HIV/AIDS in India. Clin. Immunol. 112:290-295.
3. Balzarini, J., et al. 1993. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob. Agents Chemother. 37:332-338.
4. Billick, E., et al. 2004. The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors. J. Virol. 78:4134-4144.
5. Bobardt, M. D., et al. 2008. Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus. Proc. Natl. Acad. Sci. U. S. A. 105:5525-5530.
6. Brainard, D. M., et al. 2009. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virusinfected humanized BLT mice. J. Virol. 83:7305-7321.
7. Cohen, M. S., C. Gay, A. D. Kashuba, S. Blower, and L. Paxton. 2007. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann. Intern. Med. 146:591-601.
8. Comans-Bitter, W. M., et al. 1997. Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. J. Pediatr. 130:388-393.
9. Cutler, B., and J. Justman. 2008. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect. Dis. 8:685-697.
10. Deng, Y., Q. Zheng, T. J. Ketas, J. P. Moore, and M. Lu. 2007. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor. Biochemistry 46: 4360-4369.
11. Denton, P. W., et al. 2008. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 5:e16.
12. Denton, P. W., et al. 2010. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS One 5:e8829.
13. Fauci, A. S., et al. 2008. HIV vaccine research: the way forward. Science 321:530-532.
14. Feldblum, P. J., et al. 2008. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 3:e1474.
15. Fiebig, E. W., et al. 2003. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17:1871-1879.
16. Gao, Y., J. B. Dickerson, F. Guo, J. Zheng, and Y. Zheng. 2004. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc. Natl. Acad. Sci. U. S. A. 101:7618-7623.
17. Garcia-Lerma, J. G., et al. 2008. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 5:e28.
18. Grant, R. M., et al. 2010. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363:2587-2599.
19. Halpern, V., et al. 2008. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One 3:e3784.
20. Hatziioannou, T., et al. 2009. A macaque model of HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 106:4425-4429.
21. Hladik, F., G. Lentz, E. Delpit, A. McElroy, and M. J. McElrath. 1999. Coexpression of CCR5 and IL-2 in human genital but not blood T cells: implications for the ontogeny of the CCR5+ Th1 phenotype. J. Immunol. 163:2306-2313.
22. Keenihan, S. N., and S. A. Robertson. 2004. Diversity in phenotype and steroid hormone dependence in dendritic cells and macrophages in the mouse uterus. Biol. Reprod. 70:1562-1572.
23. Kilmarx, P. H., et al. 2008. A randomized, placebo-controlled trial to assess the safety and acceptability of use of carraguard vaginal gel by heterosexual couples in Thailand. Sex Transm. Dis. 35:226-232.
24. Kim, S. S., et al. 2010. RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol. Ther. 18:370-376.
25. Lan, P., N. Tonomura, A. Shimizu, S. Wang, and Y. G. Yang. 2006. Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood 108:487-492.
26. Landovitz, R. J. 2007. Recent efforts in biomedical prevention of HIV. Top. HIV Med. 15:99-103.
27. Lederman, M. M., et al. 2004. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306:485-487.
28. Li, Q., et al. 2009. Glycerol monolaurate prevents mucosal SIV transmission. Nature 458:1034-1038.
29. McCormack, S., et al. 2010. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 376:1329-1337.
30. McGowan, I. 2010. Microbicides for HIV prevention: reality or hope? Curr. Opin. Infect. Dis. 23:26-31.
31. Melkus, M. W., et al. 2006. Humanized mice mount specific adaptive and innate immune response to EBV and TSST-1. Nat. Med. 12:1316-1322.
32. Miller Jenkins, L. M., et al. 2007. Specificity of acyl transfer from 2-mercaptobenzamide thioesters to the HIV-1 nucleocapsid protein. J. Am. Chem. Soc. 129:11067-11078.
33. Mosier, D. E. 2009. How HIV changes its tropism: evolution and adaptation? Curr. Opin. HIV AIDS 4:125-130.
34. Nkwanyana, N. N., et al. 2009. Impact of human immunodeficiency virus 1 infection and inflammation on the composition and yield of cervical mononuclear cells in the female genital tract. Immunology 128:e746-e757.
35. Nunn, A., et al. 2009. Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention. Trials 10:99.
36. Oladepo, D. K., et al. 2009. Establishment of reference values of CD4 and CD8 lymphocyte subsets in healthy Nigerian adults. Clin. Vaccine Immunol. 16:1374-1377.
37. Palmer, S., et al. 2003. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 41:4531-4536.
38. Parikh, U. M., et al. 2009. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J. Virol. 83:10358-10365.
39. Pontow, S., B. Harmon, N. Campbell, and L. Ratner. 2007. Antiviral activity of a Rac GEF inhibitor characterized with a sensitive HIV/SIV fusion assay. Virology 368:1-6.
40. Prakash, M., M. S. Kapembwa, F. Gotch, and S. Patterson. 2001. Higher levels of activation markers and chemokine receptors on T lymphocytes in the cervix than peripheral blood of normal healthy women. J. Reprod. Immunol. 52:101-111.
41. Rajesh, D., et al. 2010. Th1 and Th17 immunocompetence in humanized NOD/SCID/IL2 null mice. Hum. Immunol. 71:551-559.
42. Saita, Y., M. Kondo, and Y. Shimizu. 2007. Species selectivity of smallmolecular antagonists for the CCR5 chemokine receptor. Int. Immunopharmacol. 7:1528-1534.
43. Schinazi, R. F., et al. 1992. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother. 36:2423-2431.
44. Skoler-Karpoff, S., et al. 2008. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebocontrolled trial. Lancet 372:1977-1987.
45. Sun, Z., et al. 2007. Intrarectal transmission, systemic infection and CD4+ T cell depletion in humanized mice infected with HIV-1. J. Exp. Med. 204: 705-714.
46. Tsai, C. C., et al. 2004. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res. Hum. Retroviruses 20:11-18.
47. Van Damme, L., et al. 2002. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360:971-977.
48. Veazey, R. S. 2008. Microbicide safety/efficacy studies in animals: macaques and small animal models. Curr. Opin. HIV AIDS 3:567-573.
49. Veazey, R. S., et al. 2003. Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J. Exp. Med. 198:1551-1562.
50. Veazey, R. S., et al. 2005. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 438:99-102.
51. Vermund, S. H., and L. Van Damme. 2011. HIV prevention in women: next steps. Science 331:284.
52. Wallace, G. S., et al. 2009. Human immunodeficiency virus type 1 nucleocapsid inhibitors impede trans infection in cellular and explant models and protect nonhuman primates from infection. J. Virol. 83:9175-9182.
53. Wei, B. L., et al. 2005. Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection. J. Virol. 79:5705-5712.
54. Welch, B. D., et al. 2010. Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J. Virol. 84:11235-11244.
55. WHO and the Joint United Nations Programme on HIV/AIDS. 2009. AIDS epidemic update 2009. World Health Organization, Geneva, Switzerland. http://data.unaids.org/pub/Report/2009/jc1700_epi_update_2009_en.pdf.
56. Wolf, K., et al. 2003. Tenofovir resistance and resensitization. Antimicrob. Agents Chemother. 47:3478-3484.
57. Zeitlin, L., et al. 2001. Tests of Buffergel for contraception and prevention of sexually transmitted diseases in animal models. Sex Transm. Dis. 28:417-423.